USAMMDA Broad-Spectrum Snakebite Antidote developers take Program Management award during MHSRS (IMAGE)
Caption
The Honorable Mr. Lester Martinez-Lopez, Assistant Secretary of Defense for Health Affairs, presents the MHSRS and Defense Health Agency Award for Program Management to the U.S. Army Medical Materiel Development Activity’s Broad Spectrum Snakebite Antidote (BSSA) development team as part of the Military Health System Research Symposium, Kissimmee, Florida, Aug. 14, 2023. Kendra Lawrence, Lindsey Garver and Andrea Renner, all leaders with USAMMDA’s Warfighter Protection and Acute Care Project Management Office, and commercial partner Ophirex, Inc., were honored for the BSSA program. They accelerated the technical and programmatic maturity of the critical life-saving drug, varespladib, including two pivotal clinical trials in four years. Their efforts will provide an important capability for warfighters deployed in far-forward, austere conditions where snakebites are a significant threat to life and limb. This team’s drug development effort, funded by the Defense Health Agency, is the direct result of a collaboration between the integrated product team and their small-business partner to identify and mitigate risks early in development and to identify and implement regulatory, financial, contracting, and acquisition planning mechanisms to realize benefits for the program. As the premier developer of world-class military medical capabilities, USAMMDA is responsible for developing and delivering critical drugs, vaccines, biologics, devices, and medical support equipment to protect and preserve the lives of warfighters across the globe.
Credit
Cameron E. Parks
Usage Restrictions
No restrictions.
License
Public Domain